Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
NCT07348965Recruiting
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- Mar 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) and leptomeningeal metastasis (LM) (2 cohorts), sponsored by Guangzhou University of Chinese Medicine. Primary endpoint: Leptomeningeal Disease Control Rate at 3 years. Started Mar 2026; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT07348965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348965.